Diagnostic value of clot formation parameters determined by rotational thromboelastometry in 63 patients with congenital dysfibrinogenemia.
Journal
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
ISSN: 1473-5733
Titre abrégé: Blood Coagul Fibrinolysis
Pays: England
ID NLM: 9102551
Informations de publication
Date de publication:
22 Jan 2024
22 Jan 2024
Historique:
medline:
22
1
2024
pubmed:
22
1
2024
entrez:
22
1
2024
Statut:
aheadofprint
Résumé
Rotational thromboelastometry (ROTEM) is a global hemostasis assay. The diagnosis added value of ROTEM in congenital dysfibrinogenemia remains to be established. The aim of this study was to analyze clot formation by ROTEM in a cohort of dysfibrinogenemic patients and to establish correlations with genotype, clinical features, and coagulation parameters. The study included genetically confirmed congenital dysfibrinogenemia cases (n = 63) and healthy controls (n = 50). EXTEM, INTEM, FIBTEM tests were used to measure ROTEM parameters, that is, clotting time (CT), clot formation time (CFT), maximal clot firmness (MCF) and amplitude 10 min after CT (A10). The ISTH bleeding assessment tool was used to determine bleeding episodes. CT (INTEM) was statistically significantly shorter in congenital dysfibrinogenemia patients compared to controls while CFT (EXTEM) was prolonged. Patients's MCF in EXTEM, INTEM, and FIBTEM were similar to controls while A10 (FIBTEM) was statistically significantly lower. Fibrinogen activity was positively correlated with fibrinogen antigen, A10 and MCF in all three assays. Bleeding phenotypes were observed in 23 (36.5%) patients. Only CFT in EXTEM and CT in INTEM were statistically different in patients with bleeding phenotype versus controls. Carriers of the FGA mutation p.Arg35His had a CT (EXTEM) slightly prolonged and a reduced A10 (FIBTEM) compared to controls. Some ROTEM parameters were able to distinguish congenital dysfibrinogenemia patients from controls, and patients with a bleeding phenotype. Prolonged CFT in EXTEM were associated with congenital dysfibrinogenemia and bleeding phenotype. Bleeding episodes in most patients were generally mild and prevalence of thrombosis was very low.
Identifiants
pubmed: 38251440
doi: 10.1097/MBC.0000000000001274
pii: 00001721-990000000-00124
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Casini A, Undas A, Palla R, Thachil J, de Moerloose P. Subcommittee on Factor XIII and Fibrinogen Diagnosis and classification of congenital fibrinogen disorders: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16:1887–1890.
Casini A, Neerman-Arbez M, Ariëns RA, de Moerloose P. Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. J Thromb Haemost 2015; 13:909–919.
Simurda T, Zolkova J, Kolkova Z, Loderer D, Dobrotova M, Skornova I, et al. Comparison of clinical phenotype with genetic and laboratory results in 31 patients with congenital dysfibrinogenemia in northern Slovakia. Int J Hematol 2020; 111:795–802.
Casini A, de Moerloose P. How I treat dysfibrinogenemia. Blood 2021; 138:2021–2030.
Undas A. How to assess fibrinogen levels and fibrin clot properties in clinical practice? Semin Thromb Hemost 2016; 42:381–388.
Carll T, Wool GD. Basic principles of viscoelastic testing. Transfusion 2020; 6:1–9.
Amgalan A, Allen T, Othman M, Ahmadzia HK. Systematic review of viscoelastic testing (TEG/ROTEM) in obstetrics and recommendations from the women's SSC of the ISTH. J Thromb Haemost 2020; 18:1813–1838.
Erdoes G, Koster A, Levy JH. Viscoelastic coagulation testing: use and current limitations in perioperative decision-making. Anesthesiology 2021; 135:342–349.
Ross CR, Subramanian S, Navarro-Puerto J, Subramanian K, Kalappanavar NK, Khayat CD, et al. Pharmacokinetics, surrogate efficacy and safety evaluations of a new human plasma-derived fibrinogen concentrate (FIB Grifols) in adult patients with congenital afibrinogenemia. Thromb Res 2021; 199:110–118.
Simurda T, Asselta R, Zolkova J, Brunclikova M, Dobrotova M, Kolkova Z, et al. Congenital afibrinogenemia and hypofibrinogenemia: laboratory and genetic testing in rare bleeding disorders with life-threatening clinical manifestations and challenging management. Diagnostics (Basel) 2021; 11:2140.
Galanakis DK, Neerman-Arbez M, Brennan S, Rafailovich M, Hyder L, Travlou O, et al. Thromboelastographic phenotypes of fibrinogen and its variants: clinical and nonclinical implications. Thromb Res 2014; 133:1115–1123.
Szanto T, Lassila R, Lemponen M, Lehtinen E, Neerman-Arbez M, Casini A. Whole blood thromboelastometry by ROTEM and thrombin generation by genesia according to the genotype and clinical phenotype in congenital fibrinogen disorders. Int J Mol Sci 2021; 22:2286.
Wei A, Liao L, Xiang L, Yan J, Yang W, Nai G, et al. Congenital dysfibrinogenaemia assessed by whole blood thromboelastography. Int J Lab Hematol 2018; 40:459–465.
Zhou J, Xin Y, Ding Q, Jiang L, Chen Y, Dai J, et al. Thromboelastography predicts risks of obstetric complication occurrence in (hypo)dysfibrinogenemia patients under nonpregnant state. Clin Exp Pharmacol Physiol 2016; 43:149–156.
Zhou J, Ding Q, Chen Y, Ouyang Q, Jiang L, Dai J, et al. Clinical features and molecular basis of 102 Chinese patients with congenital dysfibrinogenemia. Blood Cells Mol Dis 2015; 55:308–315.
Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977; 74:5463–5467.
Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010; 8:2063–2065.
Schmidt DE, Majeed A, Bruzelius M, Odeberg J, Holmström M, Ågren A. A prospective diagnostic accuracy study evaluating rotational thromboelastometry and thromboelastography in 100 patients with von Willebrand disease. Haemophilia 2017; 23:309–318.
Treliński J, Pachniewska K, Matczak J, Robak M, Chojnowski K. Assessment of selected ROTEM parameters, kinetics of fibrinogen polymerization and plasmin amidolytic activity in patients with congenital fibrinogen defects. Adv Clin Exp Med 2016; 25:1255–1263.
de Vries JJ, Veen CSB, Kruip MJHA, de Maat MPM. FIBTEM clot firmness parameters correlate well with the fibrinogen concentration measured by the Clauss assay in patients and healthy subjects. Scand J Clin Lab Invest 2020; 80:600–605.
Sugo T, Endo H, Matsuda M, Ohmori T, Madoiwa S, Mimuro J, et al. A classification of the fibrin network structures formed from the hereditary dysfibrinogens. J Thromb Haemost 2006; 4:1738–1746.
Mannucci PM, Franchini M. Classic thrombophilic gene variants. Thromb Haemost 2015; 114:885–889.
Khunakanan S, Akaraborworn O, Sangthong B, Thongkhao K. Correlation between maximum clot firmness in FIBTEM and fibrinogen level in critical trauma patients. Crit Care Res Pract 2019; 2019:2756461.
Lang T, Bauters A, Braun SL, Pötzsch B, von Pape KW, Kolde HJ, Lakner M. Multicentre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis 2005; 16:301–310.
Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2007; 27:1687–1693.
Whiting D, DiNardo JA. TEG and ROTEM: technology and clinical applications. Am J Hematol 2014; 89:228–232.
Smith SA, Travers RJ, Morrissey JH. How it all starts: initiation of the clotting cascade. Crit Rev Biochem Mol Biol 2015; 50:326–336.
Heim C, Schoettker P. Viscoelastic tests of hemostasis. In: Marcucci C, Schoettker P, editors. Perioperative hemostasis. Berlin, Heidelberg: Springer; 2015. https://doi.org/10.1007/978-3-642-55004-1_3
Shapiro SE, Phillips E, Manning RA, Morse CV, Murden SL, Laffan MA, et al. Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia. Br J Haematol 2013; 160:220–227.
Casini A, Blondon M, Lebreton A, Koegel J, Tintillier V, de Maistre E, et al. Natural history of patients with congenital dysfibrinogenemia. Blood 2015; 125:553–561.
Korte W, Poon MC, Iorio A, Makris M. Thrombosis in inherited fibrinogen disorders. Transfus Med Hemother 2017; 44:70–76.
Hincker A, Feit J, Sladen RN, Wagener G. Rotational thromboelastometry predicts thromboembolic complications after major noncardiac surgery. Crit Care 2014; 18:549.